Figure 5.

Depletion of SR-A⁺ cells requires CD8⁺ T cells for effect. Mice were challenged with 5 x 10⁶ ID8-C3 cells and treated with weekly peritoneal injections of either SRA-ZAP, with untargeted toxin (Zap), anti-CD8 antibody (CD8), or with SRA-ZAP and anti-CD8 antibody (CD8/SRA). Four variables of tumor progression were assessed for each treatment group. Peritoneal exudates were measured for the ascites volume (A), total numbers of cells within the ascites (after RBC lysis; B), the quantity of GFP⁺ ID8-C3 tumor cells (C), and the quantity of CD11c⁺ VLCs (D). CD11c⁺ VLCs and GFP⁺ tumor cells were quantified by FACS analysis. Statistical significance (SRA vs ZAP, **P < .01, ***P < .005; SRA vs CD8/SRA, #P < .05, ##P < .01) was determined with the paired Student's t test.